Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells

Annals of Surgery

Volumn 235, Issue 4, 2002, Pages 540-549

  Nair, Smita K ^a   Morse, Michael ^b   Boczkowski, David ^a   Ian Cumming, R ^a   Vasovic, Ljiljana ^c   Gilboa, Eli ^a   Kim Lyerly, H ^a,b  

^a Center for Genetic and Cellular Therapies   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; MESSENGER RNA; TUMOR ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; COLON CANCER; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; LUNG CANCER; LYMPHOCYTE FUNCTION; MALE; METASTASIS; MIXED CELL CULTURE; MONONUCLEAR CELL; PRIORITY JOURNAL; RNA EXTRACTION; T LYMPHOCYTE ACTIVATION; TECHNIQUE;

ADENOCARCINOMA; AGED; ANTIGENS, NEOPLASM; COLONIC NEOPLASMS; DENDRITIC CELLS; FEASIBILITY STUDIES; HUMANS; IMMUNOTHERAPY, ACTIVE; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0036203164     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-200204000-00013     Document Type: Article

References (29)

1. New opportunities for the development of cancer immunotherapies
2. Cellular and biological therapies of gastrointestinal tumors: Overview of clinical trials
3. Tumour immunotherapy: The adjuvant treatment of the 21st century?
4. Antigen processing and presentation by the class I major histocompatibility complex
5. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
6. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma
7. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
8. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21
9. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma
10. + melanoma patients by mature monocytederived dendritic cells
11. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0210-specific peptides from prostate-specific membrane antigen
12. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
13. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
14. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
15. Dendritic cells and the control of immunity
16. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
17. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity
18. Induction of antitumor immunity using bone marrow-generated dendritic cells
19. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity
20. Dendritic cells pulsed with RNA are potent antigen presenting cells in vitro and in vivo
21. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
22. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant associated lymphoma
23. Proliferating dendritic cell progenitors in human blood
24. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with GM-CSF, IL-4, and TNF-α for use in cancer immunotherapy
25. Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides
26. A fluorescence-based assay for quantitation of lymphokine-activated killer cell activity
27. Green fluorescent protein as a marker for gene expression
28. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma
29. Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial